全文获取类型
收费全文 | 692篇 |
免费 | 36篇 |
国内免费 | 40篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 43篇 |
妇产科学 | 8篇 |
基础医学 | 69篇 |
口腔科学 | 25篇 |
临床医学 | 82篇 |
内科学 | 165篇 |
皮肤病学 | 7篇 |
神经病学 | 12篇 |
特种医学 | 172篇 |
外科学 | 63篇 |
综合类 | 16篇 |
预防医学 | 17篇 |
眼科学 | 5篇 |
药学 | 56篇 |
肿瘤学 | 27篇 |
出版年
2022年 | 2篇 |
2021年 | 8篇 |
2020年 | 3篇 |
2019年 | 5篇 |
2018年 | 11篇 |
2017年 | 11篇 |
2016年 | 6篇 |
2015年 | 12篇 |
2014年 | 21篇 |
2013年 | 12篇 |
2012年 | 12篇 |
2011年 | 12篇 |
2010年 | 23篇 |
2009年 | 30篇 |
2008年 | 12篇 |
2007年 | 34篇 |
2006年 | 15篇 |
2005年 | 9篇 |
2004年 | 9篇 |
2003年 | 10篇 |
2002年 | 12篇 |
2001年 | 10篇 |
2000年 | 8篇 |
1999年 | 14篇 |
1998年 | 51篇 |
1997年 | 44篇 |
1996年 | 38篇 |
1995年 | 29篇 |
1994年 | 24篇 |
1993年 | 34篇 |
1992年 | 8篇 |
1991年 | 16篇 |
1990年 | 9篇 |
1989年 | 26篇 |
1988年 | 19篇 |
1987年 | 24篇 |
1986年 | 13篇 |
1985年 | 19篇 |
1984年 | 15篇 |
1983年 | 15篇 |
1982年 | 16篇 |
1981年 | 16篇 |
1980年 | 18篇 |
1979年 | 2篇 |
1978年 | 9篇 |
1977年 | 7篇 |
1976年 | 7篇 |
1975年 | 5篇 |
1974年 | 1篇 |
1973年 | 1篇 |
排序方式: 共有768条查询结果,搜索用时 15 毫秒
101.
High molecular weight kininogen: localization in the unstimulated and activated platelet and activation by a platelet calpain(s) 总被引:5,自引:0,他引:5
High mol wt kininogen (HMWK), the major cofactor-substrate of the contact phase of coagulation, is contained within and secreted by platelets. Studies have been performed to localize platelet HMWK in both the unstimulated and activated platelet and to ascertain the effect of platelet enzymes on HMWK itself. On platelet subcellular fractionation, platelet HMWK was localized to alpha-granules, and platelets from a patient with a deficiency of these granules (gray platelet syndrome) had 28% normal platelet HMWK. Platelet HMWK, in addition to being secreted from the platelet, was also localized to the surface of the platelet when activated. Using a competitive enzyme- linked immunosorbent assay for HMWK as an indirect antibody consumption assay, the external membrane of thrombin-activated platelets as well as the releasate from these stimulated platelets had 17 ng HMWK antigen/10(8) platelets available, whereas unstimulated platelets and their supernatant had only 4.9 and 4.2 ng HMWK/10(8) platelets present, respectively. The anti-HMWK antibody consumption by activated normal platelets was specific for membrane-expressed platelet HMWK, since activated platelets from a patient with total kininogen deficiency did not adsorb the anti-HMWK antibody. Enzymes in the cytosolic fraction of platelets cleaved 125I-HMWK (mol wt 120,000) into a mol wt 100,000 polypeptide as well as smaller products at mol wt 74,000, mol wt 62,000, mol wt 47,000, and a few components below mol wt 45,000. No cleavage products were observed when DFP and leupeptin were present. The cleavage of HMWK was specifically prevented by inhibitors of calcium-activated cysteine proteases (leupeptin, N-ethylmaleimide, iodoacetamide, and EDTA) but not by inhibitors of serine proteases (DFP, benzamidine, soybean trypsin inhibitor, or aprotinin). Platelet cytosol increased the coagulant activity of exogenous purified HMWK with maximum HMWK coagulant activity (35-fold) occurring within ten minutes of exposure to platelet cytosol. Treatment of platelet cytosol with leupeptin prevented the increase in the coagulant activity of exogenous HMWK. These studies indicate that activated platelets express platelet HMWK on their external membrane and platelet enzymes can cleave and increase the coagulant activity of exogenous HMWK. 相似文献
102.
Background
Few studies have described patients with foregut dysmotility in inflammatory bowel disease. The aim of this case series was to evaluate clinical characteristics of 5 patients with inflammatory bowel disease and symptoms and signs of upper gut dysmotility. 相似文献103.
104.
High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission 总被引:14,自引:9,他引:14
Freedman AS; Gribben JG; Neuberg D; Mauch P; Soiffer RJ; Anderson KC; Pandite L; Robertson MJ; Kroon M; Ritz J; Nadler LM 《Blood》1996,88(7):2780-2786
We report the results of a study in previously untreated advanced stage patients with follicular lymphoma (FL) who underwent uniform induction chemotherapy with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) followed by myeloablative therapy and anti-B-cell monoclonal antibody purged autologous bone marrow transplantation (ABMT). Eighty-three patients with previously untreated, low-grade FL were enrolled. After CHOP induction, only 36% achieved complete remission (CR) and 77 patients underwent ABMT. Before BM harvest, 70 patients had a known t(14;18), as determined by polymerase chain reaction (PCR), and all remained PCR positive in the BM at harvest. After ABMT, the disease-free survival (DFS) and overall survival are estimated to be 63% and 89% at 3 years, respectively, with a median follow-up of 45 months. Patients whose BM was PCR negative after purging experienced significantly longer freedom from recurrence (FFR) than those whose BM remained PCR positive (P = .0006). Continued PCR negativity in follow-up BM samples was also strongly predictive of continued CR. This study suggests that a subset of patients with advanced FL may experience prolonged clinical and molecular remissions following high-dose ablative therapy, although longer follow-up will be necessary to determine potential impact on overall survival. 相似文献
105.
Calcium-dependent cysteine protease activity in the sera of patients with thrombotic thrombocytopenic purpura 总被引:1,自引:0,他引:1
Plasma and serum from patients with thrombotic thrombocytopenic purpura (TTP) can cause activation and aggregation of normal human platelets in vitro. It is possible that this platelet-activating factor contributes to the disease. In this report we describe studies designed to identify the platelet-activating factor in TTP. Platelet activation by sera from 15 patients with TTP was inhibited by leupeptin, iodoacetamide, and antipain but not by phenylmethylsulphonylfluoride, epsilon-aminocaproic acid, soybean trypsin inhibitor, aprotinin, and D-phenylanyl-1-prolyl-1- arginine chloromethyl ketone. These studies suggested that the platelet- activating factor in TTP serum was a cysteine protease. We confirmed that a calcium-dependent cysteine protease (CDP) was present in the sera of each of the 15 patients when we used an assay based on the ability of CDP to proteolyse platelet membrane glycoprotein 1b (GP1b) and hence to abolish the ability of CDP-treated normal platelets to agglutinate in the presence of ristocetin and von Willebrand factor. This proteolytic activity was inhibited by EDTA, leupeptin, antipain, iodoacetamide, and by N-ethyl-maleamide (NEM) but not by the serine protease inhibitors. Activity was detected in 15 of 15 patients with TTP tested before therapy was begun. In contrast, no activity was detected in the serum of any of five of the TTP patients tested in remission or in any of the sera from 36 patients with thrombocytopenia and 423 nonthrombocytopenic controls. To look for in vivo CDP activity in patients with TTP, we studied platelets from two patients with acute TTP (drawn into acid-citrate-dextrose, NEM, and leupeptin). These platelets showed a loss of GP1b from the platelet surface. Both patients were also studied in remission: GP1b on the platelet surface had returned to normal. These studies provide evidence that CDP is present in the sera of patients with TTP, that it is specific to this disease, and that is is active in vivo as well as in vitro. We postulate that a disorder of CDP homeostasis plays a major role in the pathophysiology of TTP. 相似文献
106.
107.
Internal mammary compartment: window to the mediastinum 总被引:1,自引:0,他引:1
108.
109.
Prevention of transfusion-associated graft-versus-host disease: selection of an adequate dose of gamma radiation 总被引:1,自引:0,他引:1
To determine the optimal dose of gamma radiation necessary to inhibit T- lymphocyte function and prevent transfusion-acquired graft-versus-host disease (TA-GVHD), a donor plateletpheresis component was initially divided into ten 20-mL samples. One sample was not irradiated, while the other nine samples were treated with gamma radiation at doses ranging from 500 to 4500 cGy. T-lymphocyte function was subsequently measured by mixed lymphocyte cultures and mitogen stimulation assays. The results were assessed in each test by calculating the percentage of inhibition of each irradiated sample as compared to that of the unirradiated sample. The accuracy of the delivered dose of gamma radiation was measured with thermoluminescent dosimeters. It was concluded that a nominal dose of 3000 cGy (actual dose delivered, 2898 cGy) is the appropriate amount of gamma radiation needed to eliminate T- lymphocyte-mediated graft-versus-host disease. 相似文献
110.